HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal

  • RnM3875473
  • |
  • 05 February, 2020
  • |
  • 63 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Check Discount on this report



Purchase this Report

$6,995.00
$13,990.00
$20,985.00
5,281.23
10,562.45
15,843.68
6,141.61
12,283.22
18,424.83
994,479.15
1,988,958.30
2,983,437.45
599,261.65
1,198,523.30
1,797,784.95
Credit card Logo